NCT00592579

A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma

Phase 2, Open-Label, Safety, and Efficacy Study of 2-Methoxyestradiol Administered to Patients With Plateau Phase or Relapsed Multiple Myeloma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: CASI Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to determine the safety and effectiveness of providing 2-methoxyestradiol to patients with plateau phase or relapsed multiple myeloma. Information regarding trough 2ME2 levels will also be collected.

Conditions

• Relapsed Multiple Myeloma
• Plateau Phase Multiple Myeloma

Interventions

Type	Name	Description
DRUG	2-methoxyestradiol	800 mg of 2ME2 (capsules) administered orally every 12 hours for a total daily dose of 1600 mg.

Timeline

• Start date: 2001-03-01
• Primary completion: 2008-09-01
• Completion: 2008-09-01
• First posted: 2008-01-14
• Last updated: 2009-02-26

Locations

2 sites across 1 country: United States